-
For the treatment of multiple myeloma, the second-generation proteasome inhibitor was approved in China
Time of Update: 2021-08-10
In a phase 3 clinical trial called ASPIRE, 792 patients with relapsed or refractory multiple myeloma received carfilzomib in combination with lenalidomide and dexamethasone ( KRd) combination regimen or lenalidomide and dexamethasone (Rd) regimen .
-
JAMA Oncology Shanghai Jiaotong University and other institutions cooperated, Academician Pei Zhengkang revealed that dasatinib is more effective in treating children with Philadelphia chromosome-positive acute lymphoblastic leukemia
Time of Update: 2021-08-10
iNature requires a randomized clinical trial to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib (dasatinib) is better than the first-generation inhibitor imatinib mesylate in the treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) is more effective .
-
Sanofi's $1 billion bet on new targets, which strong doctor on the multiple myeloma circuit, Mai Meng broke the news
Time of Update: 2021-08-10
Click on the picture and register now July 9, 2021 Japan/MedClub News/--Recently, Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSKCC) and Sanofi reached a license agreement on the "non-CAR use of human GPRC5D binding domain", aiming to develop potential Multiple myeloma therapy .
-
Due to safety issues, the FDA suspends a clinical trial of cell therapy for hemophilia, Sigilon's stock price plummets
Time of Update: 2021-08-10
. Recently, FDA suspended the encapsulated cell therapy clinical trials Sigilon Therapeutics company's treatment of hemophilia A type .
Sigilon Therapeutics developed the hemophilia type A cell therapy numbered SIG-001, which aims to restore the patient’s ability to produce coagulation factors.
-
Prof. Dehui Zou: Clinical Features and Efficacy Analysis of Peripheral T-Cell Lymphoma The 6th Anti-leukemia·Lymphoma International Summit Forum
Time of Update: 2021-08-10
In order to further promote the communication and development in the field of leukemia and lymphoma diagnosis at home and abroad, "The 6th Anti-leukemia·Lymphoma International Summit Forum and CSCO A
-
Prof. Wenrong Huang: Problems faced in PCNSL treatment The 6th International Anti-leukemia and Lymphoma Forum
Time of Update: 2021-08-10
The results of a prospective study in 24 centers in 6 European countries showed that HD-MTX combined with high-dose cytarabine significantly improved the remission rate of PCNSL (ORR is 70%, CR rate is 46%), but it also significantly increases side effects.
-
【Weekly Questions】Inflammatory bowel disease patients with anemia, which treatment is the most appropriate?
Time of Update: 2021-08-10
While answering the questions, please leave a message with your answers and diagnosis and treatment ideas to us .
The answer will be announced tomorrow, and we will see you or leave!
-
After the EHA meeting, the big celebrities gather to talk about new developments in myeloma & lymphoma
Time of Update: 2021-08-10
In terms of treatment options, this year’s EHA meeting announced the 5-year follow-up data of the MAIA study, showing that daratumomab (Dara) combined with Rd (DRd) for the treatment of NDMM patients who are not suitable for transplantation can bring significant survival benefits, support DRd as the first-line new standard treatment .
-
Big coffee interview with Professor Cai Qingqing: The application value of new drugs in NK/T cell lymphoma
Time of Update: 2021-08-10
During this period, Yimaitong was fortunate to invite Professor Cai Qingqing from Sun Yat-sen University Cancer Center for an interview to share the application value of the new drug in the treatment of NK/T cell lymphoma (NKTCL) .
-
Express bispecific antibody + new stem cell transplantation, Janssen collaborates to develop a combination therapy for blood cancer
Time of Update: 2021-08-10
"Reference: [1] Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML).
-
Lower dose!
Time of Update: 2021-08-10
Click on the picture to register now July 10, 2021/eMedClub News/--Recently, ASC Therapeutics announced that the US FDA has approved its research second-generation gene therapy ASC618 IND application for the treatment of severe or moderate A hemophilia .
-
Big coffee interview with Professor Lin Qiu: NGS promotes AML diagnosis and treatment and MRD monitoring
Time of Update: 2021-08-09
The biggest advantage of NGS is that dozens of mutant genes related to the prognosis and recurrence of leukemia involved in the current MRD can be detected by NGS, and the relative quantitative changes of genes closely related to the patient's treatment efficacy and recurrence can be dynamically detected .
-
FDA renews approval of daratumomab-hyaluronidase combined with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma
Time of Update: 2021-08-09
S. Food and Drug Administration (FDA) approved Darzalex Faspro (Darzalex Faspro) in combination with pomalidomide and dexamethasone for multiple myeloma ( MM) Adult patients (previously received at least first-line treatment including lenalidomide and proteasome inhibitors) .
-
Express reduces the risk of disease progression by 37%, Janssen’s CD38 antibody combination is approved for second-line treatment of multiple myeloma
Time of Update: 2021-08-09
"Reference: [1] Janssen Announces US FDA Approval of DARZALEX FASPRO® (daratumumab) and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse.
-
Preventive standards, "non-" where in the future Iimerizumab provides new options for the prevention and treatment of hemophilia
Time of Update: 2021-08-09
The non-coagulation factor drug iimerizumab has the advantages of significantly lowering the risk of bleeding, long half-life, low injection frequency, and convenient administration.
-
Big coffee interview with Professor Bai Ou: Progress and prospects of diagnosis and treatment of lymphoma in the multi-omics era
Time of Update: 2021-08-09
During this period, Yimaitong specially invited Professor Bai Ou from Bethune First Hospital of Jilin University to share the latest research, opportunities and challenges in the diagnosis and treatment of lymphoma in the multi-omics era .
-
CRISPR technology knocks out PD-1, and the targeted insertion of CD19 CAR-T completes the first patient's drug delivery. Medical Meng broke the news
Time of Update: 2021-08-09
Caribou was co-founded by Nobel Laureate Professor Jennifer Doudna, aiming to use RNA-DNA hybrid sequence-mediated CRISPR gene editing system (chRDNA) to develop allogeneic cell therapy with potentially transformative effects on patients .
https:// -trial-evaluating-cb-010-a-crispr-edited-allogeneic-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma /2.
-
The treatment of hemophilia has made further progress, and Sanofi's long-acting blood coagulation factor VIII has been approved by CDE to be a breakthrough treatment!
Time of Update: 2021-08-09
On July 12, the CDE official website showed that Sanofi's injection-use recombinant human coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein (efanesoctocog alfa, rFVIIIFc-VWF-XTEN, BIVV001) was approved by CDE as a breakthrough therapy.
According to currently released clinical trial data, the fusion protein BIVV001 can extend the half-life of factor VIII by three to four times.
-
Innovative subcutaneous drug delivery!
Time of Update: 2021-08-09
Click on the picture and sign up immediately for 2021 July 14/eMedClub News/--Recently, Johnson & Johnson's Janssen company announced that the US Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody Darzalex Faspro combined with Poma Dolamine and dexamethasone are used in the second-line treatment of adult patients with multiple myeloma .
-
Otuzumab leads new changes in FL and CLL treatment strategies The 6th International Anti-leukemia and Lymphoma Forum
Time of Update: 2021-08-09
The results of the CLL14 study showed that after 12 months of fixed course of treatment with Venecla combined with the new anti-CD20 monoclonal antibody otuzumab, CLL patients can maintain disease-free status for a long time, and some patients can also maintain minimal residual disease (MRD) Of the negative state .
